• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Scientists a step closer to developing vaccine against C. difficile

Scientists a step closer to developing vaccine against C. difficile

November 8, 2013
CenterWatch Staff

A group of scientists from across Europe have launched a three-year project aimed at developing an oral vaccine against Clostridium difficile, an infection that kills around 4,000 people a year (almost four-times more than MRSA) and for which there currently is no effective treatments.

While normally harmless in healthy people, the C. difficile bacteria can prove fatal when the natural bacteria of the gut are disrupted from antibiotic use. It is common among the elderly and infection rates are estimated to be as high as 50% in those whose hospital stays exceed four weeks.

Led by Royal Holloway, the consortium has taken the novel approach of looking to produce a vaccine that can be taken orally, under the tongue, rather than via injection, by using harmless bacterial spores to carry antigens and boost immunity by targeting the protein needed for the infection to take hold.

"We believe that our approach to develop this vaccine will provide significantly greater protection against infection and relapse, than would have been achieved via injections. This method is also likely to inform the treatment of many other diseases," said Professor Simon Cutting from the School of Biological Sciences at Royal Holloway.

The project is funded by a European Union grant of approximately $8 million, with the first clinical trials expected to start in the next 18 months.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing